Holen Sie sich die Stockscreener-App
17.20
2.69%
0.45
Vorhandelsmarkt:
17.00
-0.20
-1.16%
Schlusskurs vom Vortag:
$16.75
Offen:
$16.73
24-Stunden-Volumen:
2.32M
Relative Volume:
0.77
Marktkapitalisierung:
$1.70B
Einnahmen:
$669.43M
Nettoeinkommen (Verlust:
$-609.36M
KGV:
-2.8169
EPS:
-6.1061
Netto-Cashflow:
$-507.20M
1W Leistung:
+7.84%
1M Leistung:
+12.27%
6M Leistung:
-28.87%
1J Leistung:
-50.27%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$15.49
$17.35
52-Wochen-Spanne:
$12.73
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
17.20 | 1.70B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
529.69 | 134.26B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.16 | 85.50B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.27 | 83.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.76 | 56.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.36 | 42.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-15 | Eingeleitet | UBS | Neutral |
| 2026-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2026-09-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2026-09-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-09-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2026-09-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-09-03 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2026-03-24 | Herabstufung | Goldman | Buy → Neutral |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
GSK (GSK) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Zacks Investment Research
Form DEF 14A Ultragenyx Pharmaceutical Inc For: 21 October By Investing.com - Investing.com Australia
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $33.65 According to Brokerages - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Stock Acquired by Assenagon Asset Management S.A. - MarketBeat
Six parties report the same passive stake above 5% in Ultragenyx (RARE). - Stock Titan
Form 4 Ultragenyx Pharmaceutical Inc: Howard Horn (CFO) For: 15 October - Investing.com Nigeria
Ultragenyx CFO Howard Horn sells $107,897 in company stock - Investing.com
Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi - marketscreener.com
Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi - Yahoo Finance
Ultragenyx to allow generic DOJOLVI launch from Jan 1, 2033 under settlement - TradingView
Ultragenyx Pharmaceutical Inc. (RARE.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Ultragenyx Pharmaceutical Inc. (RARE) Options Chain - Yahoo! Finance Canada
Ultragenyx Pharma Initiated at Neutral by UBS - Moomoo
Ultragenyx In The Money As PRV Income Tops $400m - Scrip
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research
Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building - MedCity News
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
Funds from operations of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH) - The Globe and Mail
Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher | PharmExec - Pharmaceutical Executive
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - Pharmaceutical Executive
Ultragenyx cashes in Genglycos-derived priority review voucher for $210M - FirstWord Pharma
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Yahoo Finance
Ultragenyx to sell rare PRV for $210 million - The Pharma Letter
Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy? - Yahoo Finance
Form PRE 14A Ultragenyx Pharmaceutical Inc For: 7 October By Investing.com - Investing.com Nigeria
Ultragenyx Pharmaceutical agrees to sell rare pediatric voucher for US$210M - Mugglehead Investment Magazine
Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize - Endpoints News
Ultragenyx shares rise 3.2% after selling FDA p... - Pluang
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9%Here's Why - MarketBeat
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity - TradingView
Ultragenyx (RARE) Stock Rises on $210M Priority Review Voucher S - GuruFocus
Ultragenyx to sell FDA priority review voucher for $210M (RARE) - Seeking Alpha
Ultragenyx to sell rare disease priority review voucher for $210m - Investing.com
Ultragenyx (RARE) Sells Rare Pediatric Disease Priority Review V - GuruFocus
Ultragenyx PharmaceuticalUnder Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih - TradingView
Ultragenyx to Sell Priority Review Voucher for $210 Million; 20% Payable to NIH - TradingView
A voucher that can speed FDA review is set to sell for $210 million. - Stock Titan
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - GlobeNewswire
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million - Proactive financial news
Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc.OSIS - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. (RARE) stock price, news, quote and history - Yahoo Finance UK
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6%Here's Why - MarketBeat
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ultragenyx Pharmaceutical Inc-Aktie (RARE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Sep 15 '26 |
Sale |
13.57 |
1,283 |
17,410 |
67,863 |
| THEODORE HUIZENGA | Officer |
Sep 15 '26 |
Proposed Sale |
13.61 |
1,283 |
17,462 |
0 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Sep 03 '26 |
Sale |
13.99 |
161 |
2,252 |
69,146 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Aug 03 '26 |
Sale |
24.92 |
1,900 |
47,348 |
92,562 |
| Horn Howard | Chief Financial Officer |
Aug 03 '26 |
Sale |
24.92 |
4,696 |
117,024 |
96,295 |
| HOWARD HORN | Officer |
Aug 03 '26 |
Proposed Sale |
24.92 |
4,696 |
117,024 |
0 |
| Horn Howard | Chief Financial Officer |
Jul 01 '26 |
Sale |
33.13 |
4,698 |
155,645 |
100,991 |
| HOWARD HORN | Officer |
Jul 01 '26 |
Proposed Sale |
33.13 |
4,698 |
155,645 |
0 |
| Sanders Corazon (Corsee) D. | Director |
Jun 15 '26 |
Sale |
25.05 |
2,000 |
50,100 |
21,095 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Jun 15 '26 |
Sale |
24.62 |
1,899 |
46,753 |
94,462 |
2.99%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):